Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
暂无分享,去创建一个
D. Hicklin | R. Kerbel | Y. Shaked | A. Ciarrocchi | Marcela Franco | Christina R. Lee | S. Man | A. Cheung | D. Chaplin | F. S. Foster | R. Benezra | Alison Cheung
[1] Takayuki Asahara,et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.
[2] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[3] W. Gerald,et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.
[4] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[5] E. Chérin,et al. A new ultrasound instrument for in vivo microimaging of mice. , 2002, Ultrasound in medicine & biology.
[6] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[7] R. Kerbel,et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.
[8] W. Gerald,et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. , 2003, Cancer cell.
[9] W. Schaper,et al. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. , 2004, Circulation research.
[10] M. Horsman,et al. Vascular‐targeting therapies for treatment of malignant disease , 2004, Cancer.
[11] S. Dimmeler,et al. Endothelial Progenitor Cells: Characterization and Role in Vascular Biology , 2004, Circulation research.
[12] R. Kerbel,et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. , 2005, Cancer research.
[13] R. D'Amato,et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.
[14] Luigi Naldini,et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.
[15] Chryso Kanthou,et al. Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.
[16] A. Rojiani,et al. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. , 2005, International journal of radiation oncology, biology, physics.
[17] B. Peters,et al. Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.
[18] Rinat Abramovitch,et al. VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells , 2006, Cell.
[19] Limor Chen,et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. , 2006, Cancer research.